These results propose for the first time a specific role for miR-26b-5p in the TGF-β pathway in CLL, suggesting that the leukemic clone in progressive cases could acquire tumor fitness advantages by regulating the homeostatic control of TGF-β/SMAD pathway during CLL progression. The gene discussed is TGFB1; the disease is B-cell chronic lymphocytic leukemia.